Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

43.63USD
22 May 2017
Change (% chg)

$0.47 (+1.09%)
Prev Close
$43.16
Open
$43.27
Day's High
$43.66
Day's Low
$43.10
Volume
1,621,284
Avg. Vol
7,423,172
52-wk High
$45.84
52-wk Low
$36.76

Latest Key Developments (Source: Significant Developments)

Abbott CEO says is optimistic about the Trump administration: Conf Call
Wednesday, 25 Jan 2017 10:15am EST 

Abbott Laboratories : Abbott says expect challenging conditions in China's nutrition market to continue in the near term: Conf Call . Abbott expects relatively flat sales growth in nutrition for Q1: Conf Call . Abbott CEO says St. Jude's fourth quarter CRM unit sales continue to struggle, but we expect that to change shortly: Conf Call . Abbott expects China nutrition sales growth to improve through 2017 : Conf Call . Abbott CEO says "in general I am optimistic" about the new administration : Conf Call . Abbott CEO says "I don't really expect changes to ACA to directly affect us": Conf Call . Abbott CEO says St. Jude acquisition helps deepen exposure into developed markets : Conf Call . Abbott CEO says the few changes that come with Trump administration in the near term, and likely impact Abbott favourably: Conf Call . Abbott CEO not focusing too much on M&A and share repurchases in the near term, focus on paying down debt: Conf Call . Abbott CEO says performance of freestyle device ouside the U.S. has been good, and Abbott is upbeat about securing U.S. approval: Conf Call . Abbott CEO says revenue growth rate for St. Jude was about 2.5 percent for the fourth quarter : Conf Call . Abbott says negative FX impact in Q1 is relatively more than other quarters : Conf Call Further company coverage: [ABT.N] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Abbott reports Q4 sales of $5.3 billion
Wednesday, 25 Jan 2017 07:30am EST 

Abbott Laboratories : Abbott reports fourth-quarter 2016 results . Q4 GAAP earnings per share $0.51 from continuing operations . Q4 earnings per share view $0.65 -- Thomson Reuters I/B/E/S . Sees Q1 adjusted earnings per share $0.42 to $0.44 from continuing operations excluding items . Sees FY 2017 adjusted earnings per share $2.40 to $2.50 from continuing operations excluding items . Sees Q1 2017 GAAP earnings per share $0.19 to $0.21 from continuing operations . Sees FY 2017 GAAP earnings per share $0.92 to $1.02 from continuing operations . Q4 sales $5.3 billion versus I/B/E/S view $5.38 billion . Q4 adjusted earnings per share $0.65 from continuing operations excluding items . Abbott Laboratories qtrly total pediatric sales $977 million versus $1,034 million . Abbott Laboratories qtrly total nutrition sales $1,733 million versus. $1,800 million last year . Abbott Laboratories qtrly total diagnostics sales $1,256 million versus $1,220 million last year . Abbott Laboratories qtrly total vascular sales $721 million, up 0.6 percent on an operational basis . Q4 earnings per share view $0.65, revenue view $5.38 billion -- Thomson Reuters I/B/E/S . FY2017 earnings per share view $2.46 -- Thomson Reuters I/B/E/S . Q1 earnings per share view $0.50 -- Thomson Reuters I/B/E/S.  Full Article

St. Jude to deploy cyber-security updates for Merlin remote monitoring system
Monday, 9 Jan 2017 12:08pm EST 

St Jude Medical Inc : St. Jude Medical announces cybersecurity updates . Will immediately deploy latest release of cyber security updates for its Merlin remote monitoring system . Is not aware of any cyber security incidents related to a St. Jude Medical device . Also not aware that any specific St. Jude Medical device or system in clinical use has been purposely targeted .Company also plans to implement additional updates in 2017.  Full Article

China conditionally approves Abbott Laboratories' acquisition of St Jude
Friday, 30 Dec 2016 04:18am EST 

China Commerce Ministry says:Conditionally approves Abbott Laboratories' acquisition of St Jude Medical Inc Full Article

Celgene & Agios collaborates with Abbott to develop diagnostic tests for leukemia
Wednesday, 12 Oct 2016 07:49am EDT 

Abbott Laboratories : Celgene and Agios announce collaborations with Abbott for diagnostic identification of IDH mutations in AML . Celgene - companion diagnostic technology to be utilized with Enasidenib, AG-120 development programs for relapsed/refractory acute myeloid leukemia .Celgene-Agreements with abbott to develop,commercialize companion diagnostic tests on Abbott's M2000 realtime system to identify IDH mutations in AML.  Full Article

U.S. FDA provides recommendations regarding St. Jude Medical's devices
Tuesday, 11 Oct 2016 10:09am EDT 

U.S. FDA - : U.S. FDA-Providing information, recommendations regarding St. Jude Medical's advisory on ICD and CRT-D batteries that may fail earlier than expected . u.s. Fda-Fda , st. Jude medical alerting patients, patient-caregivers, and physicians to respond immediately to elective replacement indicator alerts . U.S. FDA says St. Jude medical has initiated recall, correction of affected devices; at this time, 349,852 affected devices remain actively implanted worldwide .U.S. FDA says at this time, no information indicating that issue affects devices manufactured after May 2015.  Full Article

Terumo Corp looks to purchase portion of Abbott Laboratories' medical device business - Nikkei
Thursday, 29 Sep 2016 01:16pm EDT 

Nikkei: Terumo Corp is looking to purchase a portion of Abbott Laboratories' medical device business - Nikkei . Abbott has put some operations on auction block, and Terumo Corp has apparently made bid for cardiovascular device segment and other operations - Nikkei .Terumo Corp's potential deal to purchase Abbott Laboratories' medical device business could be worth as much as 150 billion yen - Nikkei.  Full Article

Abbott Laboratories says "Alere’s lawsuit is without merit"
Friday, 26 Aug 2016 12:26pm EDT 

Abbott Laboratories : Abbott Laboratories says "Alere’s lawsuit is without merit" . Compliant with obligations under merger agreement with Alere . "continues to work toward regulatory approvals despite Alere’s nearly six month delay in filing its 2015 10-K" ((Bangalore.newsroom@thomsonreuters.com ;)).  Full Article

Alere says filed a complaint against Abbott on Aug. 25
Friday, 26 Aug 2016 11:00am EDT 

Alere Inc : Alere issues statement . "on August 25, 2016, Alere filed a complaint against Abbott in Delaware Chancery court" . Says expect redacted version of complaint to be publicly available next week . Expect redacted version of complaint to be publicly available next week .Alere will "compel" Abbott to complete transaction in accordance with its terms.  Full Article

Abbott reports Q2 2016 GAAP earnings per share $0.40 from continuing operations
Wednesday, 20 Jul 2016 07:45am EDT 

Abbott Laboratories : Q2 total diagnostics sales $1,226 million versus $1,177 million last year . Q2 total vascular sales $ 782 million versus. $722 million last year . Excluding impact of Venezuelan operations, emerging market sales would have increased 4.8% on reported basis, 12.4% on operational basis in Q2 . Abbott reports Second-Quarter 2016 results . Q2 adjusted earnings per share $0.55 from continuing operations . Q2 gaap earnings per share $0.40 from continuing operations . Q2 earnings per share view $0.53 -- Thomson Reuters I/B/E/S . Sees FY 2016 adjusted earnings per share $2.14 to $2.24 from continuing operations . Sees FY 2016 GAAP earnings per share $1.26 to $1.36 from continuing operations . Q2 sales $5.3 billion versus i/b/e/s view $5.24 billion . Q2 total nutrition sales $1,740 million versus. $1,717 million last year . Q2 total pediatric sales $ 972 million versus. $968 million last year . Excluding impact of Venezuelan operations, worldwide nutrition sales would have increased 3.3 percent on reported basis,6.2 percent on operational basis .Fy2016 earnings per share view $2.20, revenue view $20.90 billion -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Abbott reports CE Mark for tacticath contact force ablation catheter

* Abbott announces CE Mark for tacticath™ contact force ablation catheter, sensor enabled™